Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL: Who Reports Side Effects? Age, Gender & Country Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Gender Distribution

30.3%
Female
69.7%
Male

Age Information

The average age of patients reporting adverse events with EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL is 46.5 years.

Geographic Distribution

The majority of adverse event reports for EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL originate from US.

Report Summary & Outcomes

7,225
Total Reports
7,225
As Primary/Secondary Suspect
141
Deaths Reported
535
Hospitalizations
46
Life-Threatening
34
Disabilities

Reporting Timeline

First adverse event report: 199601. Most recent report: 20250513. View full timeline →

More About EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL

EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL Full Profile Reports by Year Drug Interactions